NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Investors Meet02-07-2024
02-07-2024
NATCO PHARMA LTD. - 524816 - Reply To The Clarification Sought On News Item
Reply to the clarification sought on news item01-07-2024
NATCO PHARMA LTD. - 524816 - Clarification sought from Natco Pharma Ltd
The Exchange has sought clarification from Natco Pharma Ltd on July 1, 2024, with reference to news appeared in The Hindu Business line dated July 1, 2024 quoting "Natco Pharma mulling acquisition in RoW market to strengthen base business " The reply is awaited.01-07-2024
Natco Pharma mulling acquisition in RoW market to strengthen base business
Hyderabad-based Natco has been taking steps to expand its reach and recently invested approximately $2 million in Cellogen Therapeutics Private Ltd,a Delhi based biotech start-up28-06-2024
NATCO PHARMA LTD. - 524816 - Closure of Trading Window
Closure of Trading Window for the quarter ending June 30, 202426-06-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Change in Management
Appointment of Mr. K M V Narayana Rao as Vice President - ARD of the Company with effect from 12th June, 202413-06-2024
NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation04-06-2024
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Transcript for the Earnings call held on 28th May, 202404-06-2024